Analytics
“FDA approves AstraZeneca's Truqap (capivasertib)?” is a prediction market on Polymarket with two tradeable outcomes, Yes and No. The Yes price is the crowd's implied probability that the question resolves Yes; every trade on the public order book moves it.
The venue reports this market as closed. Its scheduled close is Apr 30, 2026. No resolved outcome is inferred from a closed or suspended state.
Vultax observes this market from Polymarket's public order book and data API and keeps its own record: 25 hourly price points from Apr 22, 2026 to May 16, 2026 (Yes between 0.3% and 25.8%); 8 loaded holder wallets, the largest ten holding 100.0% of the loaded shares; 152 recent public fills from 37 wallets. Each figure carries its observation time; nothing here is a return forecast.
Public Polymarket market/event context is available; Vultax source-pack coverage is tracked separately.
This resolved market has no live orderbook depth; the public close quote is shown for context.
Nine stops, one per figure on this page. Each stop says what the number is, why it matters, and what it reads right now for this market.
Each outcome trades as a share that pays $1 if it wins and nothing if it loses. Prices are quoted in cents, and Yes plus No add up to about one dollar.
As of market creation, the FDA's expected decision date for the specified application is April 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Truqap (capivasertib) as a treatment for metastatic hormone-sensitive prostate cancer (PTEN-deficient) by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Official listing: polymarket.com/event/fda-approves-astrazenecas-truqap-capivasertib
The Yes price read as a chance. A share at 21.5¢ means the crowd gives Yes about a 21.5% chance right now. It moves with every trade, so it is a live forecast, not a verdict.
Dollar value of shares that changed hands in the last 24 hours. High volume means the price is being tested by real money; low volume means a few trades can move it.
Dollars resting in the order book, waiting to be traded against. Deep liquidity lets a large order fill near the quoted price; thin liquidity means the price jumps when someone trades size.
The gap between the best bid and the best ask. A tight spread makes entry and exit cheap; a wide spread is a cost paid on every round trip.
The wallets holding the most shares on each side, and how much of the loaded sample the largest ten control. Concentration shows whether a market is a crowd or a handful of large positions.
The public fills, newest first: which wallet bought or sold which outcome, at what price, and when. It is the market's own diary, and every wallet on it links to a trader profile.
Hourly closes of the Yes price. The range shows how sure or split the crowd has been; the move shows which way it has been changing its mind.
Trading stops at the close time. The outcome is then settled by the resolution source named in the rules. A closed market is not resolved until the venue reports it, so the two states are shown separately.
| Trader | Outcome | Shares |
|---|---|---|
| 44444444ben | Yes | 197.29 |
| ACara | Yes | 126.17 |
| 32asdadada | Yes | 91.65 |
| Keen Falcon D40C | Yes | 20.63 |
| Oklmntrader | Yes | 20.3 |
| 2percent | Yes | 10 |
| GREYER | Yes | 7 |
| rocketcrypto | Yes | 4.99 |